IBDEI0CO ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5806,0)
 ;;=B35.3^^30^385^283
 ;;^UTILITY(U,$J,358.3,5806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5806,1,3,0)
 ;;=3^Tinea Pedis
 ;;^UTILITY(U,$J,358.3,5806,1,4,0)
 ;;=4^B35.3
 ;;^UTILITY(U,$J,358.3,5806,2)
 ;;=^119732
 ;;^UTILITY(U,$J,358.3,5807,0)
 ;;=B35.5^^30^385^282
 ;;^UTILITY(U,$J,358.3,5807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5807,1,3,0)
 ;;=3^Tinea Imbricata
 ;;^UTILITY(U,$J,358.3,5807,1,4,0)
 ;;=4^B35.5
 ;;^UTILITY(U,$J,358.3,5807,2)
 ;;=^119725
 ;;^UTILITY(U,$J,358.3,5808,0)
 ;;=B35.4^^30^385^280
 ;;^UTILITY(U,$J,358.3,5808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5808,1,3,0)
 ;;=3^Tinea Corporis
 ;;^UTILITY(U,$J,358.3,5808,1,4,0)
 ;;=4^B35.4
 ;;^UTILITY(U,$J,358.3,5808,2)
 ;;=^119704
 ;;^UTILITY(U,$J,358.3,5809,0)
 ;;=B35.8^^30^385^137
 ;;^UTILITY(U,$J,358.3,5809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5809,1,3,0)
 ;;=3^Dermatophytoses,Other
 ;;^UTILITY(U,$J,358.3,5809,1,4,0)
 ;;=4^B35.8
 ;;^UTILITY(U,$J,358.3,5809,2)
 ;;=^5000606
 ;;^UTILITY(U,$J,358.3,5810,0)
 ;;=B36.9^^30^385^272
 ;;^UTILITY(U,$J,358.3,5810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5810,1,3,0)
 ;;=3^Superficial Mycosis,Unspec
 ;;^UTILITY(U,$J,358.3,5810,1,4,0)
 ;;=4^B36.9
 ;;^UTILITY(U,$J,358.3,5810,2)
 ;;=^5000611
 ;;^UTILITY(U,$J,358.3,5811,0)
 ;;=D69.0^^30^385^32
 ;;^UTILITY(U,$J,358.3,5811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5811,1,3,0)
 ;;=3^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,5811,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,5811,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,5812,0)
 ;;=B00.9^^30^385^158
 ;;^UTILITY(U,$J,358.3,5812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5812,1,3,0)
 ;;=3^Herpesviral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,5812,1,4,0)
 ;;=4^B00.9
 ;;^UTILITY(U,$J,358.3,5812,2)
 ;;=^5000480
 ;;^UTILITY(U,$J,358.3,5813,0)
 ;;=B02.9^^30^385^291
 ;;^UTILITY(U,$J,358.3,5813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5813,1,3,0)
 ;;=3^Zoster w/o Complications
 ;;^UTILITY(U,$J,358.3,5813,1,4,0)
 ;;=4^B02.9
 ;;^UTILITY(U,$J,358.3,5813,2)
 ;;=^5000501
 ;;^UTILITY(U,$J,358.3,5814,0)
 ;;=D17.9^^30^385^89
 ;;^UTILITY(U,$J,358.3,5814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5814,1,3,0)
 ;;=3^Benign Lipomatous Neop,Unspec
 ;;^UTILITY(U,$J,358.3,5814,1,4,0)
 ;;=4^D17.9
 ;;^UTILITY(U,$J,358.3,5814,2)
 ;;=^5002020
 ;;^UTILITY(U,$J,358.3,5815,0)
 ;;=E08.621^^30^385^134
 ;;^UTILITY(U,$J,358.3,5815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5815,1,3,0)
 ;;=3^DM d/t Underlying Condition w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,5815,1,4,0)
 ;;=4^E08.621
 ;;^UTILITY(U,$J,358.3,5815,2)
 ;;=^5002534
 ;;^UTILITY(U,$J,358.3,5816,0)
 ;;=E09.621^^30^385^133
 ;;^UTILITY(U,$J,358.3,5816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5816,1,3,0)
 ;;=3^DM d/t Drug/Chemical w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,5816,1,4,0)
 ;;=4^E09.621
 ;;^UTILITY(U,$J,358.3,5816,2)
 ;;=^5002576
 ;;^UTILITY(U,$J,358.3,5817,0)
 ;;=H05.011^^30^385^110
 ;;^UTILITY(U,$J,358.3,5817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5817,1,3,0)
 ;;=3^Cellulitis of Right Orbit
 ;;^UTILITY(U,$J,358.3,5817,1,4,0)
 ;;=4^H05.011
 ;;^UTILITY(U,$J,358.3,5817,2)
 ;;=^5004560
 ;;^UTILITY(U,$J,358.3,5818,0)
 ;;=H05.012^^30^385^103
 ;;^UTILITY(U,$J,358.3,5818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5818,1,3,0)
 ;;=3^Cellulitis of Left Orbit
 ;;^UTILITY(U,$J,358.3,5818,1,4,0)
 ;;=4^H05.012
 ;;^UTILITY(U,$J,358.3,5818,2)
 ;;=^5004561
 ;;^UTILITY(U,$J,358.3,5819,0)
 ;;=H05.013^^30^385^97
 ;;^UTILITY(U,$J,358.3,5819,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5819,1,3,0)
 ;;=3^Cellulitis of Bilateral Orbits
